Patents by Inventor Kristina Yucius

Kristina Yucius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Complement factor B (CFB) iRNA compositions and methods of use thereof
    Patent number: 11965166
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the complement factor B (CFB) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CFB gene and to methods of treating or preventing a CFB-associated disease in a subject.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: April 23, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James D. McIninch, Mark K. Schlegel, Adam Castoreno, Elane Fishilevich, Kristina Yucius
  • COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240018515
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the complement factor B (CFB) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CFB gene and to methods of treating or preventing a CFB-associated disease in a subject.
    Type: Application
    Filed: October 27, 2022
    Publication date: January 18, 2024
    Inventors: James D. McIninch, Adam Castoreno, Mark K. Schlegel, Elane Fishilevich, Kristina Yucius, Charalambos Kaittanis
  • COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230257749
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the complement factor B (CFB) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CFB gene and to methods of treating or preventing a CFB-associated disease in a subject.
    Type: Application
    Filed: March 22, 2023
    Publication date: August 17, 2023
    Inventors: James D. McIninch, Mark K. Schlegel, Adam Castoreno, Elane Fishilevich, Kristina Yucius
  • COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220364088
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria (PNH), lupis nephritis (LN), bullous pemphigoid, pemphigus, e.g., pemphigus vulgaris (PV) and pemphigus foliaceus (PF), and C3 glomerulopathy.
    Type: Application
    Filed: April 15, 2022
    Publication date: November 17, 2022
    Inventors: Mark Keating, James D. McIninch, Elane Fishilevich, Kristina Yucius, Sarah Solomon, Mark K. Schlegel, Adam Castoreno, Charalambos Kaittanis